Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 31, 2026.

MUSCLEMOTION

Luca Sala, Berend J. van Meer, Leon G.J. Tertoolen and 24 more

Circulation Research · 2018 · Review

doi:10.1101/160754

Abstract

Rationale:. There are several methods to measure cardiomyocyte and muscle contraction, but these require customized hardware, expensive apparatus, and advanced informatics or can only be used in single experimental models. Consequently, data and techniques have been difficult to reproduce across models and laboratories, analysis is time consuming, and only specialist researchers can quantify data.

Objective:. Here, we describe and validate an automated, open-source software tool (MUSCLEMOTION) adaptable for use with standard laboratory and clinical imaging equipment that enables quantitative analysis of normal cardiac contraction, disease phenotypes, and pharmacological responses.

Methods and Results:. MUSCLEMOTION allowed rapid and easy measurement of movement from high-speed movies in (1) 1-dimensional in vitro models, such as isolated adult and human pluripotent stem cell-derived cardiomyocytes; (2) 2-dimensional in vitro models, such as beating cardiomyocyte monolayers or small clusters of human pluripotent stem cell-derived cardiomyocytes; (3) 3-dimensional multicellular in vitro or in vivo contractile tissues, such as cardiac “organoids,” engineered heart tissues, and zebrafish and human hearts. MUSCLEMOTION was effective under different recording conditions (bright-field microscopy with simultaneous patch-clamp recording, phase contrast microscopy, and traction force microscopy). Outcomes were virtually identical to the current gold standards for contraction measurement, such as optical flow, post deflection, edge-detection systems, or manual analyses. Finally, we used the algorithm to quantify contraction in in vitro and in vivo arrhythmia models and to measure pharmacological responses.

Conclusions:. Using a single open-source method for processing video recordings, we obtained reliable pharmacological data and measures of cardiac disease phenotype in experimental cell, animal, and human models.

References 35

  1. 1.

    Laverty H, Benson C, Cartwright E, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011;163:675-693.

    Not in our library10.1111/j.1476-5381.2011.01255.x

  2. 2.

    Passier R, Orlova V, Mummery C. Complex tissue and disease modeling using hiPSCs. Cell Stem Cell. 2016;18:309-321.

    Not in our library10.1016/j.stem.2016.02.011

  3. 3.

    Bellin M, Marchetto MC, Gage FH, Mummery CL. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol. 2012;13:713-726.

    Not in our library10.1038/nrm3448

  4. 4.

    van Meer BJ, Tertoolen LG, Mummery CL. Concise review: measuring physiological responses of human pluripotent stem cell derived cardiomyocytes to drugs and disease. Stem Cells. 2016;34:2008-2015.

    Not in our library10.1002/stem.2403

  5. 5.

    Kitaguchi T, Moriyama Y, Taniguchi T, et al. CSAHi study: evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia–effects of 7 reference compounds at 10 facilities. J Pharmacol Toxicol Methods. 2016;78:93-102.

    Not in our library10.1016/j.vascn.2015.12.002

  6. 6.

    Hwang HS, Kryshtal DO, Feaster TK, Sánchez-Freire V, Zhang J, Kamp TJ, Hong CC, Wu JC, Knollmann BC. Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. J Mol Cell Cardiol. 2015;85:79-88.

    Not in our library10.1016/j.yjmcc.2015.05.003

  7. 7.
    Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function · 2015
    No notice
  8. 8.

    Ribeiro AJ, Ang YS, Fu JD, Rivas RN, Mohamed TM, Higgs GC, Srivastava D, Pruitt BL. Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc Natl Acad Sci USA. 2015;112:12705-12710.

    Not in our library10.1073/pnas.1508073112

  9. 9.

    Ribeiro AJS, Schwab O, Mandegar MA, Ang YS, Conklin BR, Srivastava D, Pruitt BL. Multi-imaging method to assay the contractile mechanical output of micropatterned human iPSC-derived cardiac myocytes. Circ Res. 2017;120:1572-1583.

    Not in our library10.1161/circresaha.116.310363

  10. 10.

    Kijlstra JD, Hu D, Mittal N, Kausel E, van der Meer P, Garakani A, Domian IJ. Integrated analysis of contractile kinetics, force generation, and electrical activity in single human stem cell-derived cardiomyocytes. Stem Cell Reports. 2015;5:1226-1238.

    Not in our library10.1016/j.stemcr.2015.10.017

  11. 11.

    Stoehr A, Neuber C, Baldauf C, Vollert I, Friedrich FW, Flenner F, Carrier L, Eder A, Schaaf S, Hirt MN, Aksehirlioglu B, Tong CW, Moretti A, Eschenhagen T, Hansen A. Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. Am J Physiol Heart Circ Physiol. 2014;306:H1353-H1363.

    Not in our library10.1152/ajpheart.00705.2013

  12. 12.

    Hayakawa T, Kunihiro T, Ando T, Kobayashi S, Matsui E, Yada H, Kanda Y, Kurokawa J, Furukawa T. Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: correlation and complementarity with extracellular electrophysiology. J Mol Cell Cardiol. 2014;77:178-191.

    Not in our library10.1016/j.yjmcc.2014.09.010

  13. 13.

    Hayakawa T, Kunihiro T, Dowaki S, Uno H, Matsui E, Uchida M, Kobayashi S, Yasuda A, Shimizu T, Okano T. Noninvasive evaluation of contractile behavior of cardiomyocyte monolayers based on motion vector analysis. Tissue Eng Part C Methods. 2012;18:21-32.

    Not in our library10.1089/ten.tec.2011.0273

  14. 14.

    Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281-2308.

    Not in our library10.1038/nprot.2013.143

  15. 15.

    Mannhardt I, Breckwoldt K, Letuffe-Brenière D, et al. Human engineered heart tissue: analysis of contractile force. Stem Cell Reports. 2016;7:29-42.

    Not in our library10.1016/j.stemcr.2016.04.011

  16. 16.

    van den Berg CW, Elliott DA, Braam SR, Mummery CL, Davis RP. Differentiation of human pluripotent stem cells to cardiomyocytes under defined conditions. Methods Mol Biol. 2016;1353:163-180.

    Not in our library10.1007/7651_2014_178

  17. 17.

    Sala L, Yu Z, Ward-van Oostwaard D, van Veldhoven JP, Moretti A, Laugwitz KL, Mummery CL, IJzerman AP, Bellin M. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. EMBO Mol Med. 2016;8:1065-1081.

    Not in our library10.15252/emmm.201606260

  18. 18.
    Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells · 2017
    No notice
  19. 19.

    Sala L, Ward-van Oostwaard D, Tertoolen LGJ, Mummery CL, Bellin M. Electrophysiological analysis of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) using multi-electrode arrays (MEAs) [published online ahead of print May 12, 2017]. J Vis Exp.

    Not in our library10.3791/55587

  20. 20.

    Ribeiro MC, Tertoolen LG, Guadix JA, Bellin M, Kosmidis G, D’Aniello C, Monshouwer-Kloots J, Goumans MJ, Wang YL, Feinberg AW, Mummery CL, Passier R. Functional maturation of human pluripotent stem cell derived cardiomyocytes in vitro–correlation between contraction force and electrophysiology. Biomaterials. 2015;51:138-150.

    Not in our library10.1016/j.biomaterials.2015.01.067

  21. 21.

    MacQuaide N, Ramay HR, Sobie EA, Smith GL. Differential sensitivity of Ca2+ wave and Ca2+ spark events to ruthenium red in isolated permeabilised rabbit cardiomyocytes. J Physiol. 2010;588:4731-4742.

    Not in our library10.1113/jphysiol.2010.193375

  22. 22.

    Lodder EM, De Nittis P, Koopman CD, et al. GNB5 mutations cause an autosomal-recessive multisystem syndrome with sinus bradycardia and cognitive disability. Am J Hum Genet. 2016;99:704-710.

    Not in our library10.1016/j.ajhg.2016.06.025

  23. 23.

    Rocchetti M, Sala L, Rizzetto R, et al. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. Cardiovasc Res. 2014;104:37-48.

    Not in our library10.1093/cvr/cvu188

  24. 24.

    Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198-205.

    Not in our library10.1038/415198a

  25. 25.

    Sala L, Bellin M, Mummery CL. Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come? Br J Pharmacol. 2016;97:2684.

    Not in our library10.1111/bph.13577

  26. 26.

    Rodriguez ML, Graham BT, Pabon LM, Han SJ, Murry CE, Sniadecki NJ. Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts. J Biomech Eng. 2014;136:051005.

    Not in our library10.1115/1.4027145

  27. 27.

    Zhang M, D’Aniello C, Verkerk AO, Wrobel E, Frank S, Ward-van Oostwaard D, Piccini I, Freund C, Rao J, Seebohm G, Atsma DE, Schulze-Bahr E, Mummery CL, Greber B, Bellin M. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci USA. 2014;111:E5383-E5392.

    Not in our library10.1073/pnas.1419553111

  28. 28.

    Bullen A. Microscopic imaging techniques for drug discovery. Nat Rev Drug Discov. 2008;7:54-67.

    Not in our library10.1038/nrd2446

  29. 29.

    Vandenburgh H, Shansky J, Benesch-Lee F, Barbata V, Reid J, Thorrez L, Valentini R, Crawford G. Drug-screening platform based on the contractility of tissue-engineered muscle. Muscle Nerve. 2008;37:438-447.

    Not in our library10.1002/mus.20931

  30. 30.

    Cavero I, Holzgrefe H. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative. Expert Opin Drug Saf. 2014;13:745-758.

    Not in our library10.1517/14740338.2014.915311

  31. 31.

    Rocchetti M, Sala L, Dreizehnter L, et al. Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovasc Res. 2017;113:531-541.

    Not in our library10.1093/cvr/cvx006

  32. 32.

    Burridge PW, Li YF, Matsa E, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016;22:547-556.

    Not in our library10.1038/nm.4087

  33. 33.

    Bellin M, Mummery CL. Stem cells: the cancer’s gone, but did chemotherapy damage your heart? Nat Rev Cardiol. 2016;13:383-384.

    Not in our library10.1038/nrcardio.2016.88

  34. 34.

    Nunes SS, Miklas JW, Liu J, et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 2013;10:781-787.

    Not in our library10.1038/nmeth.2524

  35. 35.

    Chan YC, Ting S, Lee YK, Ng KM, Zhang J, Chen Z, Siu CW, Oh SK, Tse HF. Electrical stimulation promotes maturation of cardiomyocytes derived from human embryonic stem cells. J Cardiovasc Transl Res. 2013;6:989-999.

    Not in our library10.1007/s12265-013-9510-z

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.